These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21068714)

  • 1. [18F]FDG-PET/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy.
    Martoni AA; Fanti S; Zamagni C; Rosati M; De Iaco P; D'Errico Grigioni A; Castellucci P; Quercia S; Musto A; Ricci Maccarini L; Lopci E; Bernardi A
    Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):81-90. PubMed ID: 21068714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Vallius T; Peter A; Auranen A; Carpén O; Kemppainen J; Matomäki J; Oksa S; Roering P; Seppänen M; Grénman S; Hynninen J
    Gynecol Oncol; 2016 Jan; 140(1):29-35. PubMed ID: 26515076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [PET/CT scan with (18)F-FDG in re-staging of an atypical case of ovarian cancer].
    García Gómez FJ; Cuenca Cuenca JI; Acevedo Báñez I; Borrego Dorado I; Calvo García E; Vázquez Albertino RJ
    Rev Esp Med Nucl Imagen Mol; 2012; 31(4):223-4. PubMed ID: 23067691
    [No Abstract]   [Full Text] [Related]  

  • 4. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
    Koolen BB; Valdés Olmos RA; Wesseling J; Vogel WV; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Vrancken Peeters MJ
    Ann Surg Oncol; 2013 Jul; 20(7):2227-35. PubMed ID: 23456316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET).
    Miyata H; Yamasaki M; Takahashi T; Murakami K; Tanaka K; Yukinori K; Nakajima K; Takiguchi S; Morii E; Hatazawa J; Mori M; Doki Y
    Ann Surg Oncol; 2014 Feb; 21(2):575-82. PubMed ID: 24201746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (18)F-Fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) for the early detection of response to neoadjuvant chemotherapy for locally advanced rectal cancer.
    Nishimura J; Hasegawa J; Ogawa Y; Miwa H; Uemura M; Haraguchi N; Hata T; Yamamoto H; Takemasa I; Mizushima T; Nezu R; Doki Y; Mori M
    Surg Today; 2016 Oct; 46(10):1152-8. PubMed ID: 26711129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy.
    De Iaco P; Musto A; Orazi L; Zamagni C; Rosati M; Allegri V; Cacciari N; Al-Nahhas A; Rubello D; Venturoli S; Fanti S
    Eur J Radiol; 2011 Nov; 80(2):e98-103. PubMed ID: 20688446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative 18F-FDG PET/CT in the management of advanced epithelial ovarian cancer.
    Fruscio R; Sina F; Dolci C; Signorelli M; Crivellaro C; Dell'Anna T; Cuzzocrea M; Guerra L; Milani R; Messa C
    Gynecol Oncol; 2013 Dec; 131(3):689-93. PubMed ID: 24076062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Assessment of Response to Neoadjuvant Chemotherapy with 18F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer.
    Chung YS; Kim HS; Lee JY; Kang WJ; Nam EJ; Kim S; Kim SW; Kim YT
    Cancer Res Treat; 2020 Oct; 52(4):1211-1218. PubMed ID: 32599990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using 18F-FDG PET/CT.
    Ueda S; Yoshizawa N; Shigekawa T; Takeuchi H; Ogura H; Osaki A; Saeki T; Ueda Y; Yamane T; Kuji I; Sakahara H
    J Nucl Med; 2016 Aug; 57(8):1189-95. PubMed ID: 26940765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
    Gebhart G; Gámez C; Holmes E; Robles J; Garcia C; Cortés M; de Azambuja E; Fauria K; Van Dooren V; Aktan G; Coccia-Portugal MA; Kim SB; Vuylsteke P; Cure H; Eidtmann H; Baselga J; Piccart M; Flamen P; Di Cosimo S
    J Nucl Med; 2013 Nov; 54(11):1862-8. PubMed ID: 24092940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDG-PET/CT to predict optimal primary cytoreductive surgery in patients with advanced ovarian cancer: preliminary results.
    Alessi A; Martinelli F; Padovano B; Serafini G; Lorusso D; Lorenzoni A; Ditto A; Lecce F; Mira M; Donfrancesco C; Raspagliesi F; Crippa F
    Tumori; 2016; 102(1):103-7. PubMed ID: 26350201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of 18F-FDG-PET-CT for Assessment of Response to Neoadjuvant Chemotherapy in Children With Wilms Tumor.
    Qin Z; Tang Y; Wang H; Cai W; Fu H; Li J; Ma C
    J Pediatr Hematol Oncol; 2015 Jul; 37(5):396-401. PubMed ID: 25749587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer.
    Champion L; Lerebours F; Alberini JL; Fourme E; Gontier E; Bertrand F; Wartski M
    J Nucl Med; 2015 Sep; 56(9):1315-21. PubMed ID: 26159587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early (18)F-2-fluoro-2-deoxy-d-glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapy.
    Martoni AA; Zamagni C; Quercia S; Rosati M; Cacciari N; Bernardi A; Musto A; Fanti S; Santini D; Taffurelli M
    Cancer; 2010 Feb; 116(4):805-13. PubMed ID: 20052718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results.
    Buchbender C; Kuemmel S; Hoffmann O; Stahl AR; Kimmig R; Otterbach F; Ladd S; Koeninger A; Forsting M; Bockisch A; Antoch G; Heusner TA
    Acta Radiol; 2012 Jul; 53(6):628-36. PubMed ID: 22761341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET/CT with [18F] fluorodeoxyglucose in the assessment of metabolic response to neoadjuvant chemotherapy in locally advanced breast cancer.
    Duch J; Fuster D; Muñoz M; Fernández PL; Paredes P; Fontanillas M; Skaltsa K; Domènech B; Lomeña F; Pons F
    Q J Nucl Med Mol Imaging; 2012 Jun; 56(3):291-8. PubMed ID: 22695339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
    Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
    Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer.
    Avril N; Sassen S; Schmalfeldt B; Naehrig J; Rutke S; Weber WA; Werner M; Graeff H; Schwaiger M; Kuhn W
    J Clin Oncol; 2005 Oct; 23(30):7445-53. PubMed ID: 16157939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
    Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.